Protocolised Early De-Resuscitation in Septic Shock (REDUCE) (REDUCE)
Primary Purpose
Septic Shock
Status
Recruiting
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Fluid management according to the REDUCE Fluid Protocol
Standard of care
Sponsored by
About this trial
This is an interventional other trial for Septic Shock focused on measuring Septic shock, Fluid resuscitation
Eligibility Criteria
Inclusion Criteria:
- Patients admitted to ICU with the diagnosis of septic shock as defined according to the Sepsis-3 criteria (suspected or confirmed infection AND vasopressor/inotrope ongoing to maintain MAP ≥ 65 mmHg AND Lactate ≥ 2 mmol/l in the last 6 hours
Exclusion Criteria:
- Age <18 years
- Septic shock for more than 12 hours at the time of screening
- Acute burn injury >/= 10% of the body surface area
- Known pregnancy or lactating women
- Consent not obtainable due to national legislation
- Patients on chronic dialysis
- Patients that are known to be allergic to furosemide or metolazone
Sites / Locations
- University Hospital Bern, InselspitalRecruiting
- Cantonal Hospital St. GallenRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Intervention: REDUCE Protocol
Standard of Care
Arm Description
Fluid resuscitation and de-resuscitation is based on the REDUCE fluid management protocol.
Fluid resuscitation and de-resuscitation according to the standard of care
Outcomes
Primary Outcome Measures
Proportion of patient with a negative fluid balance on day 3
Proportion of patients with a negative cumulative fluid balance on day 3
Secondary Outcome Measures
Number of patients with fluid overload at day 3 and ICU discharge
Fluid overload as defined as ((input-output)/admission weight)*100
Feasibility of the REDUCE fluid protocol
Number of REDUCE fluid protocol violations
Incidence of ischemic events and severe AKI
Number of patients with:ischaemic events, severe AKI (AKIN stage 2 or more); respectively episodes of: severe hypernatremia (sodium >/= 155mmol/l), severe hypokalemia (< 3.0 mmol/l), severe metabolic alkalosis (pH >/= 7.55, bicarbonate >/= 35 mmol/l), anaphylactic reaction to diuretic drug
Ventilator-free days at day 30
Ventilator free days up to day 30
Vasopressor-free days at day 30
Vasopressor free days up to day 30
Renal replacement therapy
Need for and time on renal replacement therapy
Number of patients with need for renal replacement at 90days
Number of patients with on-going need for renal replacement at 90days
All-cause mortality
At 30days and 90 days after randomization
Full Information
NCT ID
NCT04931485
First Posted
May 14, 2021
Last Updated
May 8, 2023
Sponsor
Insel Gruppe AG, University Hospital Bern
1. Study Identification
Unique Protocol Identification Number
NCT04931485
Brief Title
Protocolised Early De-Resuscitation in Septic Shock (REDUCE)
Acronym
REDUCE
Official Title
Protocolised Early De-Resuscitation in Septic Shock (REDUCE) - a Randomised Controlled Multi-centre Feasibility Study
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 19, 2021 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Background: Recent studies have questioned the safety of current fluid resuscitation strategies in patients with septic shock as prospective and observational data suggesting that the resulting fluid overload is associated with mortality. Two strategies have evolved to prevent or minimize fluid overload: restrictive fluid administration or active removal of accumulated fluid. While several small trials show benefits with a restrictive fluid administration regimen, active protocolized de-resuscitation was scarcely evaluated. The combination of both strategies yet warrants systematic evaluation.
Aim: This study aims to assess the efficacy and feasibility of an early active de-resuscitation protocol in patients with septic shock. We hypothesize that the application of a structured early de-resuscitation protocol versus standard of care will lead to less fluid overload at day three after ICU admission.
Study Intervention: Patients admitted to the ICU with confirmed or suspected septic shock (Sepsis-3 definition) will be randomized (1:1) to either the intervention or standard of care. In the intervention arm, patients are managed according to the REDUCE fluid management protocol during resuscitation and de-resuscitation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock
Keywords
Septic shock, Fluid resuscitation
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients will be randomized to receive either fluid resuscitation/de-resuscitation according to the REDUCE protocol or standard of care.
Masking
Outcomes Assessor
Masking Description
Outcome assessors will be blinded to the treatment allocation.
Allocation
Randomized
Enrollment
170 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention: REDUCE Protocol
Arm Type
Experimental
Arm Description
Fluid resuscitation and de-resuscitation is based on the REDUCE fluid management protocol.
Arm Title
Standard of Care
Arm Type
Active Comparator
Arm Description
Fluid resuscitation and de-resuscitation according to the standard of care
Intervention Type
Other
Intervention Name(s)
Fluid management according to the REDUCE Fluid Protocol
Other Intervention Name(s)
REDUCE protocol
Intervention Description
Fluid management according to the protocol will be guided by pre-defined clinical signs for impaired perfusion and fluid overload.
Intervention Type
Other
Intervention Name(s)
Standard of care
Intervention Description
Fluid resuscitation and de-resuscitation will be managed according to the standard of care
Primary Outcome Measure Information:
Title
Proportion of patient with a negative fluid balance on day 3
Description
Proportion of patients with a negative cumulative fluid balance on day 3
Time Frame
Up to day 3 after ICU admission
Secondary Outcome Measure Information:
Title
Number of patients with fluid overload at day 3 and ICU discharge
Description
Fluid overload as defined as ((input-output)/admission weight)*100
Time Frame
From hospital admission to the end of ICU stay, on average after 7 days
Title
Feasibility of the REDUCE fluid protocol
Description
Number of REDUCE fluid protocol violations
Time Frame
From randomisation until the end of ICU stay, on average after 7 days
Title
Incidence of ischemic events and severe AKI
Description
Number of patients with:ischaemic events, severe AKI (AKIN stage 2 or more); respectively episodes of: severe hypernatremia (sodium >/= 155mmol/l), severe hypokalemia (< 3.0 mmol/l), severe metabolic alkalosis (pH >/= 7.55, bicarbonate >/= 35 mmol/l), anaphylactic reaction to diuretic drug
Time Frame
Ischemic events and AKI: From randomisation until the end of ICU stay (on average after 7 days), and at day 30; electrolyte and acid-base/medication associated safety endpoints: during ICU stay (on average 7 days)
Title
Ventilator-free days at day 30
Description
Ventilator free days up to day 30
Time Frame
Up to 30 days after randomisation
Title
Vasopressor-free days at day 30
Description
Vasopressor free days up to day 30
Time Frame
Up to 30 days after randomisation
Title
Renal replacement therapy
Description
Need for and time on renal replacement therapy
Time Frame
Up to 90 days after randomisation
Title
Number of patients with need for renal replacement at 90days
Description
Number of patients with on-going need for renal replacement at 90days
Time Frame
Up to 90 days after randomisation
Title
All-cause mortality
Description
At 30days and 90 days after randomization
Time Frame
Up to 90 days after randomisation
Other Pre-specified Outcome Measures:
Title
Daily cumulative fluid balance up to day 7
Description
Cumulative fluid balance is total input - total output
Time Frame
Throughout the ICU stay, on average 7 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients admitted to ICU with the diagnosis of septic shock as defined according to the Sepsis-3 criteria (suspected or confirmed infection AND vasopressor/inotrope ongoing to maintain MAP ≥ 65 mmHg AND Lactate ≥ 2 mmol/l in the last 6 hours
Exclusion Criteria:
Age <18 years
Septic shock for more than 12 hours at the time of screening
Acute burn injury >/= 10% of the body surface area
Known pregnancy or lactating women
Consent not obtainable due to national legislation
Patients on chronic dialysis
Patients that are known to be allergic to furosemide or metolazone
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anna S Messmer, MD
Phone
+41316325300
Email
anna.messmer@insel.ch
First Name & Middle Initial & Last Name or Official Title & Degree
Carmen A Pfortmueller, MD
Phone
+41316325300
Email
carmen.pfortmueller@insel.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anna S Messmer, MD
Organizational Affiliation
Department of Intensive Care, Inselspital, Bern University Hospital, Bern, Switzerland
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Bern, Inselspital
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna S Messmer, MD
Email
anna.messmer@insel.ch
First Name & Middle Initial & Last Name & Degree
Carmen A Pfortmueller, Prof
Email
carmen.pfortmueller@insel.ch
Facility Name
Cantonal Hospital St. Gallen
City
St. Gallen
ZIP/Postal Code
9000
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Urs Pietsch, MD
First Name & Middle Initial & Last Name & Degree
Urs Pietsch, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Protocolised Early De-Resuscitation in Septic Shock (REDUCE)
We'll reach out to this number within 24 hrs